MedKoo Cat#: 561225 | Name: Falnidamol HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Falnidamol (BIBX 1382) is an orally active, reversible, and selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase. In preclinical studies, BIBX 1382 exhibited potent inhibition of EGFR autophosphorylation with an IC₅₀ of ~10–20 nM in EGFR-overexpressing cell lines such as A431. It effectively blocked downstream signaling pathways, including ERK and AKT, and inhibited proliferation of EGFR-dependent tumor cells with GI₅₀ values in the low nanomolar range. In xenograft models, BIBX 1382 demonstrated significant antitumor activity, especially in tumors with wild-type EGFR and high receptor expression.

Chemical Structure

Falnidamol HCl
Falnidamol HCl
CAS#1216920-18-1 (2HCl)

Theoretical Analysis

MedKoo Cat#: 561225

Name: Falnidamol HCl

CAS#: 1216920-18-1 (2HCl)

Chemical Formula: C18H21Cl3FN7

Exact Mass: 0.0000

Molecular Weight: 460.76

Elemental Analysis: C, 46.92; H, 4.59; Cl, 23.08; F, 4.12; N, 21.28

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Synonym
Falnidamol HCl; Falnidamol dihydrochloride; BIBX 1382; BIBX1382; BIBX-1382; BIBX 1382BS; BIBX1382BS; BIBX-1382BS; Falnidamol.
IUPAC/Chemical Name
N8-(3-Chloro-4-fluorophenyl)-N2-(1-methyl-4-piperidinyl)-pyrimido[5,4-d]pyrimidine-2,8-diamine dihydrochloride
InChi Key
RFXGEKWBTCMDAW-UHFFFAOYSA-N
InChi Code
InChI=1S/C18H19ClFN7.2ClH/c1-27-6-4-11(5-7-27)25-18-21-9-15-16(26-18)17(23-10-22-15)24-12-2-3-14(20)13(19)8-12;;/h2-3,8-11H,4-7H2,1H3,(H,21,25,26)(H,22,23,24);2*1H
SMILES Code
CN1CCC(NC2=NC=C(N=CN=C3NC4=CC=C(F)C(Cl)=C4)C3=N2)CC1.[H]Cl.[H]Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Biological target:
Highly selective EGFR-kinase inhibitor.
In vitro activity:
EGFR stimulation also increased T47D cell proliferation. Blocking EGFR activation with BIBX1382 or gefitinib completely abolished both FDG uptake and proliferation effects. Reference: PLoS One. 2019 Sep 18;14(9):e0221294. https://pubmed.ncbi.nlm.nih.gov/31532771/
In vivo activity:
The male and female LDLR deficient mice under Western diet containing 21% fat and 0.2% cholesterol content were cotreated with control and HB-EGF ASOs for 12 weeks. An EGFR blocker BIBX1382 administration suppressed the hepatic TG secretion rate, suggesting a positive role of the HB-EGF signaling for the hepatic VLDL production. Reference: Nutr Metab Cardiovasc Dis. 2019 Mar;29(3):306-315. https://pubmed.ncbi.nlm.nih.gov/30738642/
Solvent mg/mL mM
Solubility
DMSO 19.4 42.08
Water 19.4 42.08
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 460.76 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Jung KH, Lee EJ, Park JW, Lee JH, Moon SH, Cho YS, Lee KH. EGF receptor stimulation shifts breast cancer cell glucose metabolism toward glycolytic flux through PI3 kinase signaling. PLoS One. 2019 Sep 18;14(9):e0221294. doi: 10.1371/journal.pone.0221294. PMID: 31532771; PMCID: PMC6750601. 2. Kim S, Graham MJ, Lee RG, Yang L, Kim S, Subramanian V, Layne JD, Cai L, Temel RE, Shih D, Lusis AJ, Berliner JA, Lee S. Heparin-binding EGF-like growth factor (HB-EGF) antisense oligonucleotide protected against hyperlipidemia-associated atherosclerosis. Nutr Metab Cardiovasc Dis. 2019 Mar;29(3):306-315. doi: 10.1016/j.numecd.2018.12.006. Epub 2019 Jan 9. PMID: 30738642; PMCID: PMC6452438.
In vitro protocol:
1. Jung KH, Lee EJ, Park JW, Lee JH, Moon SH, Cho YS, Lee KH. EGF receptor stimulation shifts breast cancer cell glucose metabolism toward glycolytic flux through PI3 kinase signaling. PLoS One. 2019 Sep 18;14(9):e0221294. doi: 10.1371/journal.pone.0221294. PMID: 31532771; PMCID: PMC6750601.
In vivo protocol:
1. Kim S, Graham MJ, Lee RG, Yang L, Kim S, Subramanian V, Layne JD, Cai L, Temel RE, Shih D, Lusis AJ, Berliner JA, Lee S. Heparin-binding EGF-like growth factor (HB-EGF) antisense oligonucleotide protected against hyperlipidemia-associated atherosclerosis. Nutr Metab Cardiovasc Dis. 2019 Mar;29(3):306-315. doi: 10.1016/j.numecd.2018.12.006. Epub 2019 Jan 9. PMID: 30738642; PMCID: PMC6452438.
1: Mohr EL, McMullan LK, Lo MK, Spengler JR, Bergeron É, Albariño CG, Shrivastava-Ranjan P, Chiang CF, Nichol ST, Spiropoulou CF, Flint M. Inhibitors of cellular kinases with broad-spectrum antiviral activity for hemorrhagic fever viruses. Antiviral Res. 2015 Aug;120:40-7. doi: 10.1016/j.antiviral.2015.05.003. Epub 2015 May 16. PubMed PMID: 25986249.